{"id":46661,"date":"2023-12-01T07:23:00","date_gmt":"2023-12-01T07:23:00","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=46661"},"modified":"2023-12-09T23:48:36","modified_gmt":"2023-12-09T23:48:36","slug":"oral-prep-with-tenofoviftc-increases-clearance-of-bnab-vrc01-implications-for-future-research","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/46661","title":{"rendered":"Oral\u00a0tenofovir\/FTC increases clearance of bNAb VRC01: implications for future research"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n

A paper published on 28 November 2023 in the journal Nature Communications reports a drug interaction between the drugs commonly used as PrEP and VRC01, a broadly neutralising antibody (bNAb) which was used in a large HIV prevention study. [1]<\/strong><\/p>\n

The results are from a post-hoc analysis of the VRC01 AMP study and reported that people using PrEP had 14% lower levels of the bNAb.<\/p>\n

This subsidy included 48 participants in the VRC01 AMP study, half of whom were also using TD\/FTC oral PrEP, and compared drug levels in each group.<\/p>\n

Viral clearance of VRC01 was significantly faster (0.08\u2009L\/day, p\u2009=\u20090.005) in people using PrEP. Overall drug exposure was also significantly lower (dose-normalized area-under-the-curve of VRC01 serum concentration over time was 0.29 day\/mL lower, p\u2009<\u20090.001).<\/p>\n

The authors proposed a potential mechanism linked to oral PrEP increasing serum levels of intestinal Fatty Acid Binding protein (I-FABP), a marker of epithelial intestinal permeability.<\/p>\n

VRC01 clearance is positively associated (r\u2009=\u20090.33, p\u2009=\u20090.03) with levels of serum I-FABP) which also increases when starting PrEP (p\u2009=\u20090.04) and after months of self-reported use (p\u2009=\u20090.001).<\/p>\n

comment<\/h3>\n

Although PrEP was not widely used in the Antibody Mediated Prevention (AMP) study, which only produced a minimal protection against HIV infection in a subset of participants, people who were also taking tenofovir disoproxil\/emtricitabine would have had lower levels of the antibody. <\/strong><\/p>\n

While the PrEP would have protected these participants against HIV, it might have complicated the interpretation of the impact of the antibody.<\/strong><\/p>\n

As this is the first report of an interaction between HIV drugs and HIV bNAbs these results might have implications for other research using bNAbs.<\/strong><\/p>\n

Because of the delay associated with journal publications, most new and significant drug interactions are first presented at a medical conference, especially when the findings might have safety implications for other ongoing research. <\/strong><\/p>\n

The paper was submitted to the journal six months ago, so these results could easily have been a late-breaker at the IAS conference in July. <\/strong><\/p>\n

I should also apologise in advance if the study was presented at an earlier meeting and we just missed this.<\/strong><\/p>\n

Reference<\/p>\n

    \n
  1. Huang Y\u00a0et al.<\/i>\u00a0Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.\u00a0Nat Commun<\/i>\u00a014, 7813 (2023). (28 November 2023).
    \nhttps:\/\/doi.org\/10.1038\/s41467-023-43399-5<\/a><\/li>\n
  2. VRC01 antibody only prevents minority of HIV infections: AMP study results. HTB (21 February 2023).
    \n<\/span>    https:\/\/i-base.info\/htb\/39977<\/span><\/a><\/li>\n<\/ol>\n
    <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base A paper published on 28 November 2023 in the journal Nature Communications reports a drug interaction between the drugs commonly used as PrEP and VRC01, a broadly neutralising antibody (bNAb) which was used in a large …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34,10],"tags":[],"class_list":["post-46661","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=46661"}],"version-history":[{"count":13,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46661\/revisions"}],"predecessor-version":[{"id":46785,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46661\/revisions\/46785"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=46661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=46661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=46661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}